(Bloomberg) — BioNTech SE raised $150 million in its U.S. initial public offering, pricing its shares below its target range as a wave of biotechnology listings recedes.The German company, which cut the size of the offering earlier Wednesday, sold 10 million American depositary receipts for $15 each, according to data compiled by Bloomberg. BioNTech had earlier marketed 13.2 million shares for $18 to $20 apiece.Biotech and biomedical companies, though overshadowed by so-called unicorns such as Uber Technologies Inc. with its $8.1 billion IPO in May, account for 34 of the 144 listings on U.S. exchanges this year, the data shows. …read more
Source:: Yahoo Finance
